Financial reports
20-F
2023 FY
Annual report (foreign)
28 Mar 24
20-F
2022 FY
Annual report (foreign)
30 Mar 23
20-F
2021 FY
Annual report (foreign)
24 Mar 22
20-F
2020 FY
Annual report (foreign)
25 Mar 21
20-F
2019 FY
Annual report (foreign)
27 Mar 20
20-F/A
2018 FY
Annual report (foreign) (amended)
2 Apr 19
20-F
2018 FY
Annual report (foreign)
29 Mar 19
20-F
2017 FY
Annual report (foreign)
28 Mar 18
20-F
2016 FY
Annual report (foreign)
30 Mar 17
20-F
2015 FY
Annual report (foreign)
31 Mar 16
Current reports
6-K
Current report (foreign)
25 Apr 24
6-K
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients
15 Apr 24
6-K
Report of Foreign Private Issuer
3 Apr 24
6-K
Can-Fite Reports 2023 Financial Results and Clinical Update
28 Mar 24
6-K
Report of Foreign Private Issuer
11 Mar 24
6-K
Patent has already been issued in other major markets including the U.S., EU, Japan and China
28 Feb 24
6-K
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
30 Jan 24
6-K
Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis
29 Jan 24
6-K
Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030
20 Dec 23
6-K
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
18 Dec 23
Registration and prospectus
S-8
Registration of securities for employees
5 Apr 24
POS AM
Prospectus update (post-effective amendment)
5 Apr 24
F-3/A
Shelf registration (foreign) (amended)
28 Dec 23
F-3
Shelf registration (foreign)
12 Dec 23
424B3
Prospectus supplement
22 Nov 23
POS AM
Prospectus update (post-effective amendment)
1 Sep 23
F-3
Shelf registration (foreign)
1 Sep 23
POS AM
Prospectus update (post-effective amendment)
21 Apr 23
S-8
Registration of securities for employees
21 Apr 23
POS AM
Prospectus update (post-effective amendment)
31 Mar 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
10 Apr 24
EFFECT
Notice of effectiveness
8 Jan 24
CORRESP
Correspondence with SEC
3 Jan 24
EFFECT
Notice of effectiveness
13 Sep 23
EFFECT
Notice of effectiveness
11 Sep 23
CORRESP
Correspondence with SEC
11 Sep 23
UPLOAD
Letter from SEC
8 Sep 23
EFFECT
Notice of effectiveness
25 Apr 23
EFFECT
Notice of effectiveness
13 Feb 23
CORRESP
Correspondence with SEC
8 Feb 23
Ownership
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
CVI Investments, Inc.
14 Feb 22
SC 13G/A
INTRACOASTAL CAPITAL, LLC
11 Feb 22
SC 13G/A
Hudson Bay Capital Management LP
4 Feb 22
SC 13G/A
CVI Investments, Inc.
16 Feb 21
SC 13G/A
Hudson Bay Capital Management LP
9 Feb 21
SC 13G/A
INTRACOASTAL CAPITAL, LLC
29 Jan 21
SC 13G
ARMISTICE CAPITAL, LLC
19 Jun 20
SC 13G
CVI Investments, Inc.
19 Jun 20
SC 13G
Can-Fite BioPharma Ltd.
20 Feb 20